Skip to main content

Table 2 Summary of safety data

From: Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial

n (%) Ezetimibe
(N = 42)
Statin
(N = 41)
Number of adverse events 18 (43) 16 (39)
≥1 adverse event 9 (21) 8 (20)
Serious adverse events 1 (2) 0 (0)
Serious drug-related adverse events 0 (0) 0 (0)
Deaths 0 (0) 0 (0)